IN THE SPECIFICATION

Amendment of the specification is requested under 37 C.F.R. §1.121(b)(3). Please replace the existing specification. As required by 37 C.F.R. §1.121(b)(3)(ii), a substitute specification is attached hereto in both "mark-up" and "clean" form in compliance with 37 C.F.R. §1.125(c). Applicant states in accordance with 37 C.F.R. §1.125(b) that the substitute specification includes no new matter.

IN THE CLAIMS

The following listing of claims will replace all prior versions and listings of claims in the present application.

1. (Currently amended) ~~Transdermal~~ **A transdermal** therapeutic system (TTS) comprising an active-substance-containing cement matrix, ~~characterized in that~~ **wherein** the cement matrix ~~contains~~ **comprises** a hot-meltable adhesive in which the active substance~~, Rotigotine ((-)-5,6,7,8-tetrahydro-[propyl[2-(2-thienyl)ethyl)-amino]-1-naphthol),~~ is dispersed and partly or completely dissolved**, and wherein the active substance is rotigotine**.

2. (Currently amended) **The** TTS **[[as in]]** **of** claim 1, ~~for which~~ **wherein** the active-substance-containing cement matrix is produced by **preparing a solvent-free melt of the cement matrix and** metering the ~~Rotigotine~~ **rotigotine** into the solvent-free melt ~~of the cement matrix~~ at a temperature **[[of]]** between 70°C**[[.]]** and 200°C.

3. (Currently amended) **The** TTS **[[as in]]** **of** claim 1**,** ~~or 2, in which~~ **wherein** the hot-meltable adhesive ~~consists of a mixture of~~ **comprises** an amine-resistant silicone adhesive and**, in mixture therewith,** at least one ~~suitable~~ **pharmaceutically acceptable** softener.

4. (Currently amended) **The** TTS **[[~~as in~~]]** **of** claim 3, ~~in which~~ **wherein** the **at least one** softener is an organic wax.

5. (Currently amended) **The** TTS **[[~~as in~~]]** **of** claim 3**,** ~~or 4, in which~~ **wherein** the **at least one** softener is ceresine or ozokerite.

6. (Currently amended) **The** TTS ~~as in one of the preceding claims, in which the percentile proportion of the Rotigotine in~~ **of claim 1, wherein** the cement ~~layer is~~ **matrix comprises** 4–40 weight % **rotigotine**.

7. (Currently amended) **The** TTS ~~as in one of the preceding claims, in which the percentile proportion of the Rotigotine in~~ **of claim 1, wherein** the cement ~~layer is~~ **matrix comprises** 9–30 weight % **rotigotine**.

8. (Currently amended) **The** TTS ~~**as in one of the claims 1–6, in which the percentile proportion of the Rotigotine in**~~ **of claim 1, wherein** the cement ~~**layer is**~~ **matrix comprises** 20–40 weight % **rotigotine**.

9. (Currently amended) **The** TTS ~~**as in one of the preceding claims, in which**~~ **of claim 1, wherein** the ~~**Rotigotine**~~ **rotigotine** is present ~~**as the bioeatalytic**~~ **in free-**base **form**.

10. (Currently amended) **The** TTS ~~**as in one of the preceding claims, in which**~~ **of claim 1, wherein** the active-substance-containing cement matrix ~~**additionally contains**~~ **further comprises** an internal-phase component selected from the group **consisting** of

(a) hydrophilic **[[or]]** **and** amphiphilic polymers **and mixtures thereof with pharmaceutically acceptable softeners,**

(b) hydrophilic **[[or]]** **and** amphiphilic copolymers **and mixtures thereof with pharmaceutically acceptable softeners,**

~~**(c) mixtures of (a) and/or (b) with pharmaceutically acceptable softeners**~~

[[(d)]] **(c)** condensates **[[from]]** **of** glycerin and fatty acids**,** **[[or]]**

(d) condensates of glycerin and polyols**, and**

(e) ~~**suitable**~~ mixtures of **[[the]]** components (a)–(d)**.**

11. (Currently amended) **The** TTS **[[as in]]** **of** claim **[[10]]** **1**, ~~**in which**~~ **wherein** the **active-substance-containing cement matrix further comprises at least one** internal-phase component **[[is]]** selected from the group **consisting** of polysaccharides, substituted polysaccharides, polyethylene oxides, polyvinyl acetates, polyvinyl pyrrolidones, copolymers **[[from]]** **of** polyvinyl pyrrolidone and ~~**(poly)vinyl**~~ **polyvinyl** acetate, polyethylene glycol, polypropylene glycol, copolymers **[[from]]** **of** ethylene and vinyl acetate, glycerin-fatty acid ester**s** ~~**as well as**~~ **and** mixtures of polyvinyl alcohol with glycerin.

12. (Currently amended) **The** TTS **[[as in]]** **of** claim 1, ~~**characterized in that**~~ **wherein** the cement matrix comprises

(a) 50–99 weight % of a hot-meltable adhesive**,**

(b) 4–40 weight % ~~**Rotigotine**~~ **of rotigotine,**

(c) 0–40 weight % of an internal-phase component**, and**

(d) 0–10 weight % **of** other adjuvants.

13. (Currently amended) **The** TTS **[[as in]] of** claim 12, ~~**for which**~~ **wherein** the hot-meltable adhesive ~~**(a) selected**~~ is **[[(a1)]]** an EVA adhesive, **[[(a2)]]** an SXS adhesive, or **[[(a3)]]** a mixture of (i) 70–99 weight % of an amine-resistant silicone adhesive **and** (ii) 1–30 weight % of a ~~**suitable**~~ **pharmaceutically acceptable** softener.

14. (Currently amended) **The** TTS **of claim 1,** ~~**for the continuous transdermal administration of Rotigotine, characterized in that,**~~ **wherein, upon application of the TTS on skin of a human patient, an average plasma concentration of 0.4 to 2 ng/ml rotigotine is induced in the patient** for a period of at least 5 days following **[[its]] said** application ~~**on human skin, said TTS induces in the patient an average plasma concentration of 0.4 to 2 ng per ml Rotigotine**~~.

15. (Currently amended) **The** TTS **[[as in]] of** claim 14, ~~**characterized in that the TTS induces in the patient**~~ **wherein** an average plasma concentration of 0.4 to 2 ng/ml ~~**Rotigotine**~~ **rotigotine is induced in the patient** for a period of at least 7 days **following said application**.

16. (Currently amended) **The** TTS ~~**as in one of the preceding claims**~~ **of claim 1,** ~~**characterized in that the Rotigotine**~~ **wherein, upon application of the TTS on skin of a human patient, rotigotine** is transported through the skin at a steady-state flux rate of 200–300 µg per hour.

17. (Canceled)

18. (Currently amended) ~~**Method**~~ **A method** for ~~**producing**~~ **preparing** a TTS that ~~**encompasses**~~ **comprises** a **rotigotine-containing** cement matrix, ~~**containing Rotigotine as the active substance, characterized in that prior to their lamination**~~ the **method comprising melting and homogenizing** components of the cement matrix ~~**are melted and homogenized**~~, solvent-free, **in an extruder** at ~~**temperatures**~~ **a temperature** between 70°C**[[.]]** and 200°C **prior to lamination of the components**.

19. (Canceled)

20. (Currently amended) ~~Use of Rotigotine in the production of~~ **A method for preparing** a TTS **that comprises a rotigotine-containing cement matrix** ~~by the hot-melt method, characterized in that the Rotigotine is introduced~~, **the method comprising pre-melting and homogenizing components of the cement matrix other than the rotigotine, solvent-free,** ~~the Rotigotine is introduced~~ **and introducing rotigotine** at ~~temperatures~~ **a temperature** between 70°C[[.]] and 200°C[[.]], **[[in]] into** the **[[TTS]] pre-melted** cement matrix ~~that has been premelted without solvents~~.

21. (Currently amended) ~~Method or use as in one of the preceding claims, whereby~~ **The method of Claim 20, wherein** the ~~hot-melting process takes place~~ **rotigotine is introduced into the pre-melted cement matrix** at ~~temperatures~~ **a temperature** between 120°C[[.]] and 160°C.

22. (Currently amended) ~~Method or use as in one of the preceding claims, whereby~~ **The method of Claim 20, wherein** the ~~Rotigotine~~ **rotigotine** is introduced[[,]] **in solid state into** the **pre-melted** cement[[-]] matrix ~~melt, in its solid state~~.

23. (Currently amended) ~~Method or use as in one of the preceding claims, whereby~~ **The method of Claim 20, wherein the rotigotine in** the cement matrix~~, produced by the hot-melting process, contains Rotigotine at~~ **so prepared has** a purity level of at least 98% as measured by HPLC at 220 nm and 272 nm.

24. (New) The method of Claim 18, wherein the melting takes place at a temperature between 120°C and 160°C.

25. (New) The method of Claim 20, wherein the rotigotine in the cement matrix so prepared has a purity level of at least 98% as measured by HPLC at 220 nm and 272 nm.